Methamphetamine (METH) abuse continues to escalate and effective treatments are not currently available. METH interacts with the vesicular monoamine transporter-2 (VMAT2), promoting both dopamine (DA) release into the cytosol and reversal of the DA transporter to increase extracellular DA concentrations, which is thought to be associated with its abuse liability. The overall objective of this project is to provide a clinical candidate for the treatment of METH abuse. Recently, we identified a novel small molecule (GZ-793A), which potently and selectively inhibits DA uptake by VMAT2, inhibits METH-evoked DA release from synaptic striatal vesicles and slices, and exhibits selectivity does not interact with nicotinic receptors or DA transporters. Off-target evaluation at a cadre of neurotransmitter-related, steroid and ion channel sites, second messenger, prostaglandin, growth factor and hormones, brain/gut peptides and enzymes revealed outstanding selectivity. Translation to whole animals models revealed that GZ-793A specifically decreases METH self-administration without altering responding for sucrose, does not produce tolerance to the decrease in METH self- administration upon repeated administration, and decreases METH seeking in the cue-induced reinstatement. Acute GZ793A pretreatment also protects against the neurotoxic effects of METH as measured by striatal DA depletion. Although the physicochemical properties of GZ-793A are favorable in terms of druggability, GZ-793A has only 2-3% oral bioavailability, likely due to the presence of the hydroxyl functionalities in the molecule which are likely sites for high first-pass metabolism. Thus, new optimized analogs of GZ-793A are the focus of the current application with the goal of identifying analogs with the required pharmacological properties, druggability, increased oral bioavailability, and acceptable pharmacokinetic profile. Compounds with these characteristics would be high value preclinical candidates for advancement toward clinical trials as treatments for METH abuse. Thus, we propose to expand our existing molecular library of analogs by performing the final steps of optimization of GZ-793A to identify a high value preclinical candidate as a potential therapeutics for METH abuse. In future work, the best candidate will undergo comprehensive toxicological evaluation for subsequent preparation of an Investigational New Drug application to the FDA as a proposed treatment for methamphetamine abuse.
Currently, there is no pharmacotherapeutic available for methamphetamine abuse. The overall objective of this project is to provide a clinical candidate for the treatment of methamphetamine abuse. Recently, we identified a novel small molecule (GZ-793A), which potently and selectively interacts with the vesicular monoamine transporter-2 and which exhibits potency and specificity in decreasing responding for intravenous methamphetamine in an animal model of self-administration. We propose to expand our existing molecular library by performing the final steps of optimization of the chemical structure of GZ-793A with the aim of providing additional leads that are druggable, orally-bioavailable, high value preclinical candidates. The outcome of the proposed project is to bring the best candidate to comprehensive toxicological evaluation for preparation of an Investigational New Drug application to the FDA as a proposed treatment for methamphetamine abuse.
|Lee, Na-Ra; Zheng, Guangrong; Crooks, Peter A et al. (2018) New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders. AAPS J 20:29|
|Kangiser, Megan M; Dwoskin, Linda P; Zheng, Guangrong et al. (2018) Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats. Behav Pharmacol 29:87-97|
|Shrestha, Sanjib K; Kril, Liliia M; Green, Keith D et al. (2017) Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. Bioorg Med Chem 25:58-66|
|Hankosky, Emily R; Joolakanti, Shyam R; Nickell, Justin R et al. (2017) Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett 27:5467-5472|
|Nickell, Justin R; Culver, John P; Janganati, Venumadhav et al. (2016) 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett 26:2997-3000|
|Sviripa, Vitaliy M; Burikhanov, Ravshan; Obiero, Josiah M et al. (2016) Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin. Org Biomol Chem 14:74-84|
|Joolakanti, Shyamsunder R; Nickell, Justin R; Janganati, Venumadhav et al. (2016) Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett 26:2422-2427|
|Nickell, Justin R; Culver, John P; Janganati, Venumadhav et al. (2016) Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett 26:4441-4445|
|Zheng, Guangrong; Crooks, Peter A (2015) Synthesis of Lobeline, Lobelane and their Analogues. A Review. Org Prep Proced Int 47:317-337|
|Ding, Derong; Nickell, Justin R; Dwoskin, Linda P et al. (2015) Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett 25:2613-6|
Showing the most recent 10 out of 33 publications